Tiziana rises on completing lab safety study for lead drug

Tiziana Life Sciences

15/12/2022 19:32

** Shares of drug developer Tiziana Life Sciences Ltd
 TLSA.O  rise 2.7% to 58 cents 
    ** Co completes pre-clinical safety study for its lead
candidate to treat diseases of the central nervous system (CNS)
    ** Co's experimental drug, foralumab, is an intranasal
antibody-based formulation which will be tested in a mid-stage
trial for the treatment of multiple sclerosis (MS) 
    ** MS is a disease that affects nerve cells of the brain and
the spinal cord- TLSA 
    ** TLSA plans to request a meeting with the U.S. Food and
Drug Administration (FDA) regarding mid-stage study before
year-end, expects feedback in Q1 2023
    ** Meeting with FDA for multiple sclerosis is expected to
favor testing the drug for other CNS diseases, including
Alzheimer's disease, says B.Riley Securities analyst Mayank
Mamtani
    ** Brokerage reiterates its "buy" rating and $3 PT for TLSA 
    ** Including session gains, TLSA shares down ~41.14% YTD
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))